Segment Information - Schedule of Company Revenue and Adjusted EBITDA by Segment (Details) - USD ($) $ in Thousands		3 Months Ended				6 Months Ended
		Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Revenue
Total revenue	[1]	$ 49,999		$ 75,659		$ 110,863	$ 140,172
Segment Adjusted EBITDA
Total Adjusted EBITDA		(45,053)		(29,655)		(94,853)	(79,369)
Net loss attributable to common stockholders		(75,270)	$ (104,624)	(66,065)	$ (89,532)	(179,894)	(155,597)
Adjustments
Interest income, net		(3,752)		(1,392)		(8,059)	(1,637)
Other income (expense), net		(145)		687		(477)	1,122
Provision for (benefit from) income taxes		36		(1,271)		36	(1,525)
Depreciation and amortization		4,474		5,152		8,951	10,256
Amortization of acquired intangible assets		3,638		4,267		7,277	8,582
Stock-based compensation expense		23,741		28,967		74,840	59,430
Loss on disposition of Lemonaid Health Limited and related transaction costs (3)	[2]	2,127		0		2,375	0
Litigation settlement cost		98		0		98	0
Total Adjusted EBITDA		(45,053)		(29,655)		(94,853)	(79,369)
Consumer And Research Services
Segment Revenue
Total revenue	[1]	49,999		75,659		110,863	140,172
Segment Adjusted EBITDA
Total Adjusted EBITDA		(6,673)		2,324		(12,275)	(14,673)
Therapeutics
Segment Adjusted EBITDA
Total Adjusted EBITDA		(26,224)		(18,663)		(57,363)	(37,128)
Unallocated Corporate [Member]
Segment Adjusted EBITDA
Total Adjusted EBITDA	[3]	$ (12,156)		$ (13,316)		$ (25,215)	$ (27,568)

[1] There was no Therapeutics revenue for the three and six months ended September 30, 2023 and 2022.

[2] Refer to Note 17, “Disposition of Subsidiary” for additional information

[3] Certain department expenses such as Finance, Legal, Regulatory and Supplier Quality, Corporate Communications, Corporate Development, and CEO Office are not reported as part of the reporting segments as reviewed by the CODM. These amounts are included in Unallocated Corporate.